Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine
Lam, J. H.; Khan, A. K.; Cornell, T. A.; Dress, R. J.; Chia, T. W.; Yeow, W. W. W.; Mohd-Ismail, N. K.; Venkatraman, S.; Ng, K. T.; Tan, Y.-J.; Anderson, D. E.; Ginhoux, F.; Nallani, M.
Show abstract
Multiple successful vaccines against SARS-CoV-2 are urgently needed to address the ongoing Covid-19 pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising of polybutadiene-b-polyethylene glycol and a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells, which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of memory CD4+ and CD8+ T cells that produce Th1 cytokines. This study is an important step towards the development of an efficacious vaccine in humans.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 97%
- Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model 96%
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference 96%
Similar papers in this journal
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. 97%
- TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination 95%
- Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine 95%
Similar papers in this journal
- Long-term Immunity of a Microneedle Array Patch of SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice 97%
- Cell-free screening, production and animal testing of a STI-related chlamydial major outer membrane protein supported in nanolipoproteins. 96%
- Multivalent Exosome based protein vaccine: a "mix and match" approach to epidemic viruses' challenges. 96%
Similar papers in this journal
- Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design 95%
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 95%
- Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines 95%
Similar papers in this journal
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations 96%
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice 96%
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.